Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Preliminary Eficacy of Autologous SCG142 T Cell Receptor (TCR) T Cells in Patients With Advanced or Metastatic HPV16- or HPV52-positive Carcinomas

NCT06505551 is registered in ClinicalTrials.gov with SCG Cell Therapy Pte. Ltd. as lead sponsor.

NCT NCT06505551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06505551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Preliminary Eficacy of Autologous SCG142 T Cell Receptor (TCR) T Cells in Patients With Advanced or Metastatic HPV16- or HPV52-positive Carcinomas
Lead sponsor
SCG Cell Therapy Pte. Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2024
Completion date
December 31, 2028
Enrollment
66 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related anal squamous cell carcinoma, hpv-related cervical squamous cell carcinoma, hpv-related head and neck cancer, hpv-related penile squamous cell carcinoma, hpv-related squamous cell carcinoma, hpv-related vaginal squamous cell carcinoma, hpv-related vulvar squamous cell carcinoma